Can Aimovig (Erenumab) Cause Constipation?

Understanding Erenumab and Its Digestive Effects

Aimovig (erenumab) represents a breakthrough in migraine prevention as the first FDA-approved CGRP receptor antagonist. This medication works by blocking calcitonin gene-related peptide (CGRP) receptors in the brain and nervous system, effectively reducing the frequency and severity of migraine attacks. However, CGRP receptors aren't limited to the head and neck area. They're also found throughout the gastrointestinal tract, where they play important roles in normal digestive function.

When erenumab blocks these receptors, it can inadvertently affect intestinal motility and bowel function. This mechanism explains why constipation emerges as one of the most commonly reported side effects, affecting approximately 3-15% of patients depending on the dose. The connection between CGRP pathways and digestive health means that while Aimovig effectively prevents migraines, some patients may experience changes in their bowel habits.

Unlike other digestive issues that might develop with various medications, erenumab-related constipation stems from a specific biological pathway. Understanding this connection helps patients and healthcare providers anticipate, recognize, and manage this side effect more effectively.

Clinical Evidence and Timeline

Pivotal clinical trials for Aimovig provide clear data about constipation risk. In studies involving patients with episodic migraines, constipation occurred in approximately 3% of those receiving the 70mg dose and 11% of those on the 140mg dose, compared to just 1% in the placebo group. For chronic migraine patients, the rates were slightly higher, with up to 15% experiencing constipation symptoms.

The dose-dependent relationship is particularly noteworthy. Patients receiving the higher 140mg monthly dose consistently showed increased rates of digestive side effects compared to those on 70mg. This pattern suggests that the intensity of CGRP receptor blockade directly correlates with the likelihood of developing bowel function changes.

Most patients who develop constipation notice symptoms within the first month of treatment, though some may experience changes later. The timeline often coincides with the medication reaching steady-state levels in the body, typically after the second or third injection. Early recognition of symptoms allows for prompt intervention, which can prevent more severe digestive complications.

Biological Mechanisms Behind Digestive Changes

CGRP naturally facilitates smooth muscle relaxation and promotes normal peristalsis, the wave-like contractions that move food and waste through the intestines. When erenumab blocks these receptors, it can slow down these essential digestive movements, leading to decreased bowel frequency and harder stools.

The enteric nervous system, often called the "second brain," relies heavily on CGRP signaling for optimal function. This complex network of neurons controls digestive processes independently of the central nervous system but communicates extensively with brain pathways. When CGRP receptors are blocked, this gut-brain communication can be disrupted, potentially affecting everything from gastric emptying to colonic transit time.

Individual susceptibility varies significantly based on baseline digestive health. Patients with pre-existing constipation, irritable bowel syndrome, or slower intestinal transit may be more vulnerable to developing symptoms. Age, gender, and overall health status also influence how significantly erenumab affects digestive function. Understanding these risk factors helps healthcare providers identify patients who may need additional monitoring or preventive strategies. Some patients also experience nausea and dizziness alongside constipation, highlighting the interconnected nature of digestive symptoms.

Practical Management Strategies

Effective constipation management while taking Aimovig involves a multi-faceted approach focusing on dietary modifications, hydration, and gentle interventions. Increasing soluble fiber intake through foods like oats, beans, and fruits can help soften stools and promote regular movements. However, it's important to increase fiber gradually to avoid gas and bloating, which can worsen discomfort.

Hydration plays a crucial role in preventing and managing constipation. Patients should aim for at least 8-10 glasses of water daily, though individual needs may vary based on activity level, climate, and overall health. Warm beverages, particularly in the morning, can stimulate digestive activity and encourage bowel movements.

Over-the-counter remedies can provide safe, effective relief when used appropriately. Stool softeners like docusate sodium are generally well-tolerated and can be used regularly if needed. Gentle laxatives such as polyethylene glycol or magnesium-based products offer additional options for more persistent symptoms. However, patients should consult their healthcare providers before starting any new medications to ensure compatibility with their treatment regimen.

Regular physical activity, even light walking, can significantly improve intestinal motility. Establishing consistent bathroom routines and allowing adequate time for bowel movements can also help maintain regularity. Some patients find that Heating Pad application to the abdomen provides additional comfort and may stimulate digestive activity.

Risk Factors and Prevention

Several patient characteristics increase the likelihood of developing constipation with erenumab treatment. Age is a significant factor, with older adults generally experiencing higher rates of digestive side effects. Women may also be more susceptible, possibly due to hormonal influences on digestive function and baseline differences in intestinal transit times.

Pre-existing digestive conditions warrant special attention. Patients with a history of chronic constipation, irritable bowel syndrome with constipation (IBS-C), or gastroparesis may experience worsening symptoms when starting Aimovig. Those taking other medications known to cause constipation, such as opioids or certain antidepressants, face compound risk and may need more intensive management strategies.

Preventive measures can significantly reduce the likelihood and severity of constipation. Starting a high-fiber diet and establishing good hydration habits before beginning erenumab treatment creates a foundation for healthy digestive function. Some patients benefit from starting a daily probiotic supplement to support gut microbiome health, though evidence for this approach remains limited.

Regular monitoring becomes essential once treatment begins. Patients should track bowel movement frequency, stool consistency, and any associated symptoms like abdominal pain or bloating. This information helps healthcare providers adjust management strategies and identify when more aggressive interventions may be necessary. Unlike conditions that might cause back pain, erenumab-related constipation typically responds well to early intervention.

Treatment Decisions and Alternatives

The decision to continue Aimovig despite constipation involves carefully weighing migraine prevention benefits against digestive side effects. For many patients, the significant reduction in migraine frequency and severity outweighs manageable constipation, especially when effective interventions are in place. Healthcare providers may recommend dose adjustments, starting with the lower 70mg dose and increasing only if migraine control remains inadequate.

Alternative CGRP inhibitors offer different side effect profiles that may better suit individual patients. While all CGRP antagonists can potentially cause constipation, the rates and severity vary between medications. Galcanezumab (Emgality) and fremanezumab (Ajovy) represent viable alternatives with potentially different digestive tolerance profiles.

Some patients may benefit from combination approaches, using lower doses of erenumab alongside other preventive strategies or temporary medication holidays to allow digestive function to normalize. The goal remains achieving optimal migraine control while maintaining acceptable quality of life, including comfortable digestive function.

Discontinuation becomes necessary only in cases of severe, unmanageable constipation that doesn't respond to intervention strategies. However, this decision should never be made unilaterally. Healthcare providers can often identify alternative solutions or provide more intensive management before recommending treatment cessation. With over 22 million AI consultations completed, platforms like Doctronic offer accessible guidance for navigating these complex treatment decisions, helping patients optimize their migraine care while managing side effects effectively.

The Bottom Line

Constipation is a well-documented side effect of Aimovig that affects a minority of patients but can be effectively managed with proper strategies. While erenumab's CGRP-blocking mechanism may slow intestinal function, most cases respond well to dietary modifications, increased hydration, and gentle interventions. The significant migraine prevention benefits often outweigh digestive concerns when constipation is properly addressed. Doctronic's AI consultations, which have demonstrated 99.2% treatment plan alignment with board-certified physicians, can help you navigate both migraine treatment decisions and side effect management. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.